Print

LAM Pharmaceutical Corporation's (LAMP) Licensee Ixora Bio Medical Commences Commercial Sales Of Female Sexual Enhancement 
10/19/2005 5:11:17 PM

LEWISTON, N.Y., May 12 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Ixora Bio Medical Company Inc., a licensee of LAM, has commenced commercial sales of its first product, "Ixora(TM) for Women", a non-prescription female sexual enhancement product Ixora has licensed from LAM.

John Easton, Chief Executive Officer of Ixora Bio Medical, stated, "The commercial release of "Ixora(TM) for Women" in the United States and Canada comes at a time when the medical community, media and public are recognizing that sexual health and optimal sexual function are an essential component of one's overall well being. Mr. Easton continued, "Having completed four years of extensive development, "Ixora(TM) for Women" is ready to answer the rapidly increasing demand for an upscale product that addresses the issue of women's sexual function."

Mr. Easton concluded, "With 'Ixora(TM) for Women' available through doctors' offices, women's health clinics, direct sales and on the Ixora's web site (http://www.ixoraforwomen.com/), Ixora expects that the market size and strong demand backed by the upcoming media launch will all contribute to strong sales ramp up throughout 2004."

Dr. Jack Barkin, Urologist-in-chief and chief of surgery at the Humber River Regional Hospital in Toronto, Canada stated, "Women, especially as they reach menopause, have a loss of hormonal support that contributes to decreased sexual desire. The introduction of 'Ixora(TM) for Women' provides women and their partners a natural solution to sexual enhancement."

Joseph Slechta, President and Chief Executive Officer of LAM, remarked, "We are pleased that Ixora has commenced commercial sales, marking the third product introduction based on LAM's proprietary IPM technology. As LAM's IPM Wound Gel, our veterinary product, and 'Ixora(TM) for Women' all gain acceptance in their markets, we look forward to developing more products based on our remarkable technology."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with laboratories in Lewiston, New York, and business offices in Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About Ixora Bio Medical Company Inc.

Ixora Bio Medical Company is a biomedical company with headquarters in New York City. Ixora holds a world wide exclusive license from LAM for sexual dysfunction products based on LAM's patented proprietary IPM Ionic Polymer Matrix transdermal delivery platform. The Company's current focus is to develop and commercialize sexual enhancement products. More information about Ixora can be obtained by visiting http://www.ixoraforwomen.com/.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group

LAM Pharmaceutical, Corp.

CONTACT: Stephanie Carrington of The Ruth Group, +1-646-536-7017, forLAM Pharmaceutical, Corp.


//-->